Antiviral Drugs Market size was over USD 56.69 billion in 2024 and is likely to reach USD 95.1 billion by the end of 2037, witnessing around 4.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of antiviral drugs is assessed at USD 58.55 billion. The increasing cases of hepatitis B infection and high investment in R&D activities on antiviral drugs across the world are estimated to propel the market growth during the forecast period. As per the World Health Organization, about 296 million people are suffered from chronic hepatitis B infection in 2019.
The growing incidence rate of infectious diseases such as herpes simplex virus, hepatitis virus, and influenza. As per the observations, between September to October 2022, nearly 5300 members tested positive for the influenza virus.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.2% |
|
Base Year Market Size (2024) |
USD 56.69 billion |
|
Forecast Year Market Size (2037) |
USD 95.1 billion |
Drug Class - (DNA Polymerase, Reverse Transcription, Protease, Neuraminidase Inhibitors)
The global antiviral drugs market is segmented and analyzed for demand and supply by drug class into DNA polymerases, reverse transcription, protease, and neuraminidase inhibitors. Out of these, reverse transcription is anticipated to hold the largest market size by the end of 2037 on the back of the growing diagnosis and treatment rate of HIV infection and the increasing efficiency of antiviral drugs on viral diseases. In 2021, about 29 million individuals who suffered from HIV received antiretroviral therapy.
Major Macro-Economic Indicators Impacting the Market Growth
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5,355.79, which grew from USD 3,515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in the upcoming years.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Class |
|
|
By Indication |
|
|
By Type |
|
|
By Age Group |
|
Regionally, the global antiviral drugs market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. Amongst these markets, the market in North America region is projected to hold the largest market share by the end of 2037 on the back of a growing patient base, the strong foothold of industry key players, increasing approval, and the expected commercialization of new drugs for viral diseases. In 2022, the number of COVID-19 cases increased by 8% in North America.
Merck & Co., Inc. announced that Molnupiravir, an oral antiviral investigational medicine used to reduce the risk of hospitalization or death.
Johnson & Johnson Services, Inc. declared the introduction of a multi-pronged response against novel Coronavirus. This is also used to determine the coronavirus pathophysiology to help patients survive from 2019-nCoV infection.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?